New and Emerging Topical Approaches for Actinic Keratoses

James Q. Del Rosso, DO

Accepted for publication August 20, 2003. From the Department of Dermatology, University of Nevada School of Medicine, Las Vegas.
Dr. Del Rosso has served as either a consultant or speaker, or both, for 3M Pharmaceuticals; Allergan, Inc; Berlex Laboratories; Bristol-Myers Squibb Company; Connetics Corporation; Dermik Laboratories, Inc; Galderma Laboratories, LP; GlaxoSmithKline; Healthpoint, Ltd; Janssen Pharmaceutica Products, LP; Medicis, The Dermatology Company; Novartis Pharmaceuticals Corporation; and Ortho Neutrogena.

James Q. Del Rosso, DO

Accepted for publication August 20, 2003. From the Department of Dermatology, University of Nevada School of Medicine, Las Vegas.
Dr. Del Rosso has served as either a consultant or speaker, or both, for 3M Pharmaceuticals; Allergan, Inc; Berlex Laboratories; Bristol-Myers Squibb Company; Connetics Corporation; Dermik Laboratories, Inc; Galderma Laboratories, LP; GlaxoSmithKline; Healthpoint, Ltd; Janssen Pharmaceutica Products, LP; Medicis, The Dermatology Company; Novartis Pharmaceuticals Corporation; and Ortho Neutrogena.

James Q. Del Rosso, DO

Accepted for publication August 20, 2003. From the Department of Dermatology, University of Nevada School of Medicine, Las Vegas.
Dr. Del Rosso has served as either a consultant or speaker, or both, for 3M Pharmaceuticals; Allergan, Inc; Berlex Laboratories; Bristol-Myers Squibb Company; Connetics Corporation; Dermik Laboratories, Inc; Galderma Laboratories, LP; GlaxoSmithKline; Healthpoint, Ltd; Janssen Pharmaceutica Products, LP; Medicis, The Dermatology Company; Novartis Pharmaceuticals Corporation; and Ortho Neutrogena.